en English
en Englishfr Frenchde Germanit Italianru Russianes Spanish

Upbeat earnings lift European shares; Novo Nordisk hits record high

Upbeat earnings lift European shares; Novo Nordisk hits record high By Reuters

Breaking News

‘;

Economy

Published Jan 31, 2024 03:34AM ET
Updated Jan 31, 2024 04:56AM ET

© Reuters. The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 24, 2024. REUTERS/Staff

By Shristi Achar A

(Reuters) -European shares gained on Wednesday, rising for the sixth straight session, on a boost from robust corporate updates, while investors awaited the U.S. Federal Reserve’s policy decision later in the day.

The pan-European STOXX 600 index was up 0.1% as of 0934 GMT.

Financial services rose 0.4%, lifted by a 1.1% gain in Spanish lender Santander (BME:SAN), which posted a record-high profit for the last quarter of 2023, beating forecasts.

Industrials received a push from shares of Beijer Ref, up 7.5% after the Swedish wholesaler of cooling technology reported fourth-quarter sales above expectations and forecast continued growth in 2024.

Investor attention was centred on the Fed’s interest rate verdict, due at 1900 GMT, for clues regarding the timing of interest rate cuts in the world’s largest economy.

“The Fed is likely to open the door further to rate cuts at its policy meeting today, while leaving rates on hold this month,” analysts at UBS Global Wealth Management noted.

“But recent solid growth and labor data from the U.S. suggest the Fed will likely not rush to start cutting rates at the pace markets currently expect.”

Upbeat earnings reports from Europe Inc and increasing bets around an interest rate cut from the European Central Bank drove the index to two-year highs earlier this week, and on course to clock its third straight month of gains.

Heavyweight healthcare stocks were in spotlight, with Danish drugmaker Novo Nordisk (NYSE:NVO) adding 1.4% to notch an all-time high after Europe’s most valuable company forecast another year of double-digit sales and operating profit growth due to its popular weight-loss drug Wegovy.

The stock pulled Copenhagen’s OMX 20 to a fresh record high, last up 0.9%.

Swiss drugmaker Novartis (SIX:NOVN), however, fell 4.1% on missing estimates for fourth-quarter net income, with the stock dragging healthcare sector down 0.5%.

Among others, H&M (ST:HMb) slumped 8.7% to the bottom of STOXX 600 after the Swedish fashion retailer posted a fall in fourth-quarter margin, while its CEO decided to step down.

On the data front, French consumer prices rose 3.4% year-on-year in January, a touch above expectations, but inflation slowed from the previous month, according to preliminary data. A separate reading showed German retail sales fell unexpectedly, by 1.6% in December.

Yield on Germany’s 10-year government bond fell following the data points, and was last at 2.210%, while Paris’ blue-chip CAC 40 scaled an intra-day record peak, up 0.1%. [GVD/EUR]

Upbeat earnings lift European shares; Novo Nordisk hits record high

Our Apps



Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information

© 2007-2024 Fusion Media Limited. All Rights Reserved.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post SM Group secures 20 Philippine Quill Awards
Next post GSK sees strong growth as Haleon split and vaccine drive pays off